I'll also say that this challenge is bigger than just one company. Some things may make more sense to do via Science Exchange, for example if the method requires some very customized hardware or there are only a few experts in the world who are sufficiently familiar with an unusual method's sensitivities. I'm also excited to see what Riffyn comes out with to help labs understand where reproducibility comes from. We're just getting started, but I can't see a path forward that puts more humans at benches rather than less. The humans should be free to do real science.
Your example is greatly flawed. The biggest consumers of highly parallelizeable workflows is the pharmaceutical industry. Highly parallel medchem was a big fad and the number of drugs that it produced for its efforts is disappointing. The fact that 11% of Amgen's results are irreproducible is if anything a condemnation of parallel scaleup, at least in the context of an operator with a strong motive for selective interpretation.
Another big problem is that when you bring your numbers up, you 'get what you are looking for'. Precision optimization can optimize for an artefact. I joke I like to make is that sloppy science is good, because if you keep seeing the same result under a noisy platform, what you're seeing is probably real and, more encouragingly, robust.
Molecular biology has embraced standardization and automation to a great degree but it is an outlier.
I've encountered enormous resistance from practitioners trying to apply automation into cell biology.
Biology is enormously held back from the tools for improving productivity have to come from computer science but there is huge amounts of interdisciplinary friction.
I think you could also capture an interesting market if you offered "evolution as a service" using your kit.
In order to capture a real market, you're going to have to figure out a way to offer parallelization services - be given a non-parallel experiment with certain parameters and scale it up on behalf of the users. So, the user has an experimental plan and just 'hands it over' to transcriptic. I still worry about the experiential knowledge part, putting the experimenter one step away from the experiment is potentially counterproductive.
[0]http://onlinelibrary.wiley.com/doi/10.1002/pro.2339/full In this paper, the grad student (and lead author) who had spent four years of her graduate work on a previous paper had a nagging feeling that the data were strange. By actually looking at the wells, she figured out post-publication (with nothing to gain) that the protein was sticking to sides of the 96-well plate and causing the observational data to be artefactual. Then there was the question of how to do more experiments to prove that was going on. And then the political problem of convincing her grad advisor to publish a retraction (well at least it was a retraction worth a 10 page paper and a new citation. The story has a happy ending; she got a position at a pharma company largely on the back of her due diligence).